Denali Therapeutics Inc (DNLI)

Apr 15, 2025

(DNLI) Technical Data - news.stocktradersdaily.com

Apr 15, 2025

Apr 10, 2025

Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com

Apr 10, 2025

Apr 05, 2025

Denali Therapeutics stock hits 52-week low at $12.05 By Investing.com - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

Denali Therapeutics stock hits 52-week low at $12.05 - Investing.com

Apr 04, 2025

Apr 03, 2025

Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com

Apr 03, 2025

Apr 03, 2025

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Zacks Investment Research

Apr 03, 2025

Apr 02, 2025

Denali Therapeutics set to advance groundbreaking treatments for neurological diseases - MSN

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics advances Hunter syndrome treatment BLA By Investing.com - Investing.com South Africa

Apr 02, 2025

Apr 02, 2025

What Happened To Denali Therapeutics Stock Wednesday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga

Apr 02, 2025

Apr 02, 2025

Sector Update: Health Care Stocks Advance in Late Afternoon Trading - TradingView

Apr 02, 2025

Apr 02, 2025

Sector Update: Health Care - MarketScreener

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics begins marketing application for genetic disorder drug, shares rise - TradingView

Apr 02, 2025

Apr 02, 2025

Denali Goes All In on Neuroscience’s Thorniest Hurdle: Crossing the Blood-Brain Barrier - BioSpace

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics Files Application for Accelerated Approval of Hunter Syndrome Treatment; Shares Up - MarketScreener

Apr 02, 2025

Apr 02, 2025

How another firm's FDA approval could mean a big win for Denali TherapeuticsSan Francisco Business Times - The Business Journals

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics Announces Initiation of BLA Filing for - GlobeNewswire

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics advances Hunter syndrome treatment BLA - Investing.com

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome - MarketScreener

Apr 02, 2025

Apr 02, 2025

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program - GlobeNewswire

Apr 02, 2025

Apr 02, 2025

Breakthrough: Denali's Hunter Syndrome Drug Enters Final FDA Approval Stage - Stock Titan

Apr 02, 2025

Mar 30, 2025

Trend Tracker for (DNLI) - news.stocktradersdaily.com

Mar 30, 2025

Mar 26, 2025

Denali Therapeutics stock hits 52-week low at $13.95 By Investing.com - Investing.com South Africa

Mar 26, 2025

Mar 26, 2025

Denali Therapeutics stock hits 52-week low at $13.95 - Investing.com Australia

Mar 26, 2025

Mar 21, 2025

Exponential Growth Expected for Blood Brain Barrier Market With - openPR.com

Mar 21, 2025

Mar 20, 2025

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead (NASDAQ:DNLI) - Seeking Alpha

Mar 20, 2025

Mar 20, 2025

Why You Shouldn't Bet Against Denali (DNLI) Stock - Barchart

Mar 20, 2025

Mar 20, 2025

(DNLI) On The My Stocks Page - news.stocktradersdaily.com

Mar 20, 2025

Mar 19, 2025

Denali Starts Dosing in Phase II Parkinson's Disease Study - MSN

Mar 19, 2025

Mar 13, 2025

Denali halts extension of DNL343 arm in HEALEY ALS trial - ALS News Today

Mar 13, 2025

Mar 11, 2025

Denali Therapeutics (NASDAQ:DNLI) Given New $28.00 Price Target at Bank of America - Defense World

Mar 11, 2025

Mar 11, 2025

Denali Therapeutics (NASDAQ:DNLI) Shares Down 8.9% on Analyst Downgrade - Defense World

Mar 11, 2025

Mar 10, 2025

Why Denali Therapeutics Shares Are Tumbling - TipRanks

Mar 10, 2025

Mar 10, 2025

Bank of New York Mellon Corp Decreases Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

Mar 10, 2025

Mar 10, 2025

Proficio Capital Partners LLC Makes New $514,000 Investment in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World

Mar 10, 2025

Mar 10, 2025

Denali Therapeutics (NASDAQ:DNLI) Earns Overweight Rating from Analysts at Morgan Stanley - Defense World

Mar 10, 2025

Mar 09, 2025

How the (DNLI) price action is used to our Advantage - Stock Traders Daily

Mar 09, 2025

Mar 08, 2025

B. Riley Forecasts Lower Earnings for Denali Therapeutics - Defense World

Mar 08, 2025

Mar 07, 2025

Denali's ALS programme suffers another setback - pharmaphorum

Mar 07, 2025

Mar 07, 2025

What is B. Riley’s Forecast for DNLI FY2029 Earnings? - Defense World

Mar 07, 2025

Mar 07, 2025

Morgan Stanley initiates Denali stock with Overweight rating - Investing.com

Mar 07, 2025

Mar 07, 2025

B. Riley Reaffirms Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - Defense World

Mar 07, 2025

Mar 06, 2025

Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback - Benzinga India

Mar 06, 2025

Mar 05, 2025

Denali Therapeutics discontinues active treatment extension in eIF2B Regimen G - TipRanks

Mar 05, 2025

Mar 05, 2025

Denali Therapeutics Discontinues DNL343 ALS Trial - TipRanks

Mar 05, 2025

Mar 05, 2025

DNLI stock touches 52-week low at $14.55 amid market challenges - Investing.com Australia

Mar 05, 2025

Mar 05, 2025

B. Riley Trims Price Target on Denali Therapeutics to $35 From $38, Keeps Buy Rating - MarketScreener

Mar 05, 2025

Mar 05, 2025

Denali Therapeutics (NASDAQ:DNLI) Sets New 12-Month Low Following Analyst Downgrade - Defense World

Mar 05, 2025

Mar 04, 2025

DNLI stock touches 52-week low at $14.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 04, 2025

Mar 04, 2025

Denali Therapeutics price target lowered to $42 from $50 at Oppenheimer - Yahoo Finance

Mar 04, 2025